Absent CD44v6 Expression is an Independent Predictor of Poor Urothelial Bladder Cancer Outcome

Journal of Urology

Volumn 183, Issue 6, 2010, Pages 2403-2408

  Klatte, Tobias ^a   Seligson, David B ^a   Rao, Jian Yu ^a   Yu, Hong ^a   de Martino, Michela ^a   Garraway, Isla ^a   Wong, Steven G ^a   Belldegrun, Arie S ^a   Pantuck, Allan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antigens, CD44; mortality; risk; urinary bladder neoplasms; urothelium

Indexed keywords

CD44V6 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; CYSTECTOMY; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR RECURRENCE; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 77951878563     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.01.064     Document Type: Article

References (29)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225
2. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303
3. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466
4. Klatte T., Seligson D.B., Rao J.Y., et al. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer 115 (2009) 1448
5. Malats N., Bustos A., Nascimento C.M., et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 (2005) 678
6. van Rhijn B.W., Burger M., Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56 (2009) 430
7. Martin T.A., Harrison G., Mansel R.E., et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46 (2003) 165
8. Ponta H., Wainwright D., and Herrlich P. The CD44 protein family. Int J Biochem Cell Biol 30 (1998) 299
9. Mackay C.R., Terpe H.J., Stauder R., et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124 (1994) 71
10. Sherman L., Wainwright D., Ponta H., et al. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev 12 (1998) 1058
11. Ropponen K.M., Eskelinen M.J., Lipponen P.K., et al. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 33 (1998) 301
12. Mulder J.W., Kruyt P.M., Sewnath M., et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344 (1994) 1470
13. Wielenga V.J., Heider K.H., Offerhaus G.J., et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53 (1993) 4754
14. Kaufmann M., Heider K.H., Sinn H.P., et al. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345 (1995) 615
15. Southgate J., Trejdosiewicz L.K., Smith B., et al. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer 62 (1995) 449
16. Chuang C.K., and Liao S.K. Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas. Anticancer Res 23 (2003) 4635
17. Kuncová J., Kostrouch Z., Viale M., et al. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197. Folia Biol (Praha) 51 (2005) 3
18. Ross J.S., del Rosario A.D., Bui H.X., et al. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol 9 (1996) 854
19. Lipponen P., Aaltoma S., Kosma V.M., et al. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 186 (1998) 157
20. Hong R.L., Pu Y.S., Hsieh T.S., et al. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 153 (1995) 2025
21. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844
22. Klatte T., Belldegrun A.S., and Pantuck A.J. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int, suppl 101 (2008) 45
23. Sugino T., Gorham H., Yoshida K., et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149 (1996) 873
24. Kuncová J., Urban M., and Mandys V. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. APMIS 115 (2007) 1194
25. Yang Y.M., and Chang J.W. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 26 (2008) 725
26. Naor D., Sionov R.V., and Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 71 (1997) 241
27. Heider K.H., Kuthan H., Stehle G., et al. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53 (2004) 567
28. Woodman A.C., Goodison S., Drake M., et al. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia. Clin Cancer Res 6 (2000) 2381
29. Sun Y., He D.L., Ma Q., et al. Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Engl) 119 (2006) 1763